
Merck (MRK) Stock Forecast & Price Target
Merck (MRK) Analyst Ratings
Bulls say
Merck & Co is in a prime position to leverage its robust pipeline and established products to offset the potential loss of sales from Keytruda's LOE. The company's key therapeutic areas in oncology, cardiovascular disease, and infectious diseases, and its leading Animal Health business provide a diverse and resilient revenue stream. With a strong focus on research and development, and a track record of successful launches and acquisitions, Merck is well positioned for continued growth and potential outperformance in the market.
Bears say
Merck & Co is facing significant headwinds as several key drugs are expected to face patent expirations in the coming years, leading to potential loss in revenue. However, the company has announced topline results from a pivotal Phase 3 trial for an antiretroviral treatment, indicating potential for future growth. Additionally, the company's focus on combination strategies and new drug launches may help mitigate the impact of the LOE of Keytruda. However, concerns surrounding climate change, regulatory pressures, and compliance obligations represent material challenges to the business and its reputation.
This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.
Merck (MRK) Analyst Forecast & Price Prediction
Start investing in Merck (MRK)
Order type
Buy in
Order amount
Est. shares
0 shares